Clinical Trials Logo

HER2-positive Breast Cancer clinical trials

View clinical trials related to HER2-positive Breast Cancer.

Filter by:
  • Active, not recruiting  
  • « Prev · Page 4

NCT ID: NCT00791037 Active, not recruiting - Clinical trials for HER2-positive Breast Cancer

Vaccine Therapy in Treating Patients With Stage IV Breast Cancer

Start date: October 2008
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial is studying the side effects of escalating doses of adoptive T cell therapy in treating patients with stage IV breast cancer. Vaccines are given to patient prior the expansion of a person's white blood cells may help the body build an effective immune response to kill tumor cells that overexpress human epidermal growth factor receptor 2 (HER2)

NCT ID: NCT00436254 Active, not recruiting - Clinical trials for HER2-positive Breast Cancer

Vaccine Therapy With Sargramostim (GM-CSF) in Treating Patients With Her-2 Positive Stage III-IV Breast Cancer or Ovarian Cancer

Start date: October 2001
Phase: Phase 1
Study type: Interventional

RATIONALE: Vaccines may help the body build an effective immune response to kill tumor cells. Colony-stimulating factors, such as GM-CSF, may increase the number of immune cells found in bone marrow or peripheral blood. Giving vaccine therapy together with sargramostim may be an effective treatment for breast cancer and ovarian cancer. PURPOSE: This phase I trial is studying the side effects and identifying the best dose of vaccine therapy when given together with sargramostim in treating patients with stage III-IV breast cancer or ovarian cancer.